Navigation Links
BioLineRx Reports Third Quarter 2013 Financial Results
Date:11/13/2013

JERUSALEM, Nov. 13, 2013 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, today reported its results for the third quarter ending September 30, 2013.

(Logo: http://photos.prnewswire.com/prnh/20130730/630769)

Kinneret Savitsky, Ph.D., Chief Executive Officer of BioLineRx, stated, "As we approach the end of 2013, we see the Company's continued progress towards several significant catalysts over the next several quarters. For instance, one of our most advanced assets, BL-1040 for the prevention of ventricular remodeling post AMI, is progressing as scheduled at full steam in the PRESERVATION I CE-Mark registration trial. Fifty-five sites are currently open, including 14 in the U.S., and final results are expected in 2014."

Other highlights

BL-8040 (AML and other hematological indications):

  • Granted orphan drug designation by the FDA, allowing a faster clinical path toward commercialization 
  • Added Memorial Sloan Kettering Cancer Center in New York to join the Phase 2 multi-center study, bringing the total number of sites to eight
  • Received patent allowance through 2029 from the USPTO for method of obtaining stem cells
  • "During the third quarter, we made significant progress in our Phase 2 clinical trial for BL-8040, a best-in-class CXCR4 antagonist for the treatment of hematological cancers such as AML. In September, we received orphan drug status from the FDA, a designation with significant positive implications for BL-8040 as it advances through the clinic, including a seven-year market exclusivity period, clinical protocol assistance with the FDA, and federal grants and tax credits. We remain on track to deliver partial results from the trial by the end of this year, with final results expected in the se
    '/>"/>

    SOURCE BioLineRx Ltd.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
    2. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
    3. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
    4. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
    5. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
    6. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
    7. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
    8. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
    9. BioLineRx to Present at 15th International Celiac Disease Symposium
    10. BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
    11. BioLineRx Appoints B. J. Bormann to Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/5/2015)... 2015  BioPhotas, Inc., an FDA registered medical device ... technologies to treat skin, muscle and joint conditions, today ... Fund to provide BioPhotas, flagship product, the Celluma, ... solutions.  Commenting on the alliance, ... the Celluma at the Warrior Hope and Care Center ...
    (Date:3/5/2015)... HAMILTON, N.J. , March 5, 2015 /PRNewswire/ ... laboratory which specializes in high complexity, state-of-the-art, automated ... offering new Human Papillomavirus (HPV) testing which utilizes ... platforms. Each year, approximately 12,000 women ... the United States . Genital Human Papillomaviruses ...
    (Date:3/5/2015)... 2015  ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ... acquired the approved abbreviated new drug application ("ANDA") ... 150mg, previously marketed by Teva Pharmaceuticals.  According to ... was approximately $39 million in 2014.   ... CEO of ANI Pharmaceuticals, stated, "This acquisition further ...
    Breaking Medicine Technology:BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 3ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3
    ... 2011 /PRNewswire/ -- MEDX, Inc., a ... the next generation T-Quest™ compact gamma camera.  The ... features expanded imaging capabilities to perform parathyroid, sentinel ... other small organ studies.  The Company also announced ...
    ... 6, 2011 Life Extension, a global authority on ... supplements, has launched a product featuring ChromaDex,s (CDXC.OB) pTeroPure ... food stores and natural retailers. Life Extension ... naturally found in blueberries.  Pterostilbene has been shown ...
    Cached Medicine Technology:MEDX Installs Two Next Generation T-Quest™ Compact Gamma Cameras 2MEDX Installs Two Next Generation T-Quest™ Compact Gamma Cameras 3Life Extension® Launches New Product Containing ChromaDex's pTeroPure® Pterostilbene 2Life Extension® Launches New Product Containing ChromaDex's pTeroPure® Pterostilbene 3
    (Date:3/5/2015)... 05, 2015 TCS Healthcare Technologies (TCS), ... the population health management arena, is pleased to announce ... software, ACUITY Advanced Care™ (ACUITY) version 7.20. The session ... and the advantages of automation. , The webinar, scheduled ... be led by Jeff Frater, RN, BSN, Director of ...
    (Date:3/5/2015)... PA (PRWEB) March 05, 2015 ... leader in healthcare communications and education, announced today ... (AMP), the nation’s only medical conference designed ... limb ischemia and lower limb amputation due to ... growing family of innovative, evidence-based publications and CME ...
    (Date:3/5/2015)... Los Angeles, Calif. (PRWEB) March 05, 2015 ... company and the leader in the natural products coffee ... Coffee at Natural Products Expo West in Anaheim, Calif. ... Califia’s home café concept, Califia Café, which democratizes the ... drinkers all the ingredients they need to become their ...
    (Date:3/5/2015)... Frisco, TX (PRWEB) March 05, 2015 ... Convention Center in Fort Worth, Texas April 9-11th ... and wellness company providing personalized nutrition. IDLife ... core product, IDNutrition. This customized approach to ... research that begins with a free HIPAA compliant ...
    (Date:3/5/2015)... March 05, 2015 For PASCHA Chocolate, ... most essential ingredients, the robust flavor of the cacao ... PASCHA Chocolate is free from peanuts, nuts, dairy, ... PASCHA's offering March 6th- 8th at Expo West., ... PASCHA Chocolate has broken new ground with their New ...
    Breaking Medicine News(10 mins):Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 3Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 4Health News:IDLife Partners John C. Maxwell and Troy Aikman speaking at IDRevolution in Fort Worth, TX April 9th-11th, 2015 2Health News:PASCHA Allergen Free Organic Chocolate to Appear at Natural Products Expo West March 6-8, 2015 2
    ... WOODCLIFF LAKE, N.J., Dec. 12 Par Pharmaceutical Companies, Inc. ... Veronica A. Lubatkin, executive vice president and chief financial officer, ... , , Lawrence A. ... vice president of finance and will assume the role of ...
    ... September 8, 2008, TooBusyWorking was launched as a next-generation ... openings from all major employers onto a single Web ... than CareerBuilder, HotJobs, Nurse.com and Monster combined. , ... large number of job openings, each listing on TooBusyWorking ...
    ... can be achieved. A supplement published in Malaria ... many aspects of the research agenda for global malaria ... progress that has been made in the development of ... prevention. Elimination requires a different vaccine strategy, since success ...
    ... Terumo Corporation and Terumo,s,subsidiary, Terumo Cardiovascular Systems ... agreement to settle all outstanding litigation with,Maquet Cardiovascular, ... lawsuits pending,in which each claims the other has ... and devices used in endoscopic vessel harvesting. ...
    ... /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS, NASDAQ: DDSS ... of the Toronto Stock Exchange, today commented on the ... is not aware of any reason for the recent ... Fee Act (PDUFA) action date for its once-daily formulation ...
    ... To protect the security of online file access from Internet fraud, ... its existing program Vetted QuickBase. , ... Raleigh, NC ... further protects its online file access from web fraud ...
    Cached Medicine News:Health News:Par Pharmaceutical Announces the Resignation of Its Chief Financial Officer 2Health News:Malaria Journal supplement evaluates steps toward elimination 2Health News:Labopharm Comments on Recent Trading Activity 2Health News:To Further Combat Internet Fraud, Heightened Security Levels are Implemented by Vetted International 2Health News:To Further Combat Internet Fraud, Heightened Security Levels are Implemented by Vetted International 3
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: